{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:22:26Z","timestamp":1792030946688,"version":"4.4.0"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40265-024-02096-3","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T04:11:42Z","timestamp":1728015102000},"page":"1365-1378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Orexin Receptor Antagonists for the Prevention and Treatment of Alzheimer\u2019s Disease and Associated Sleep Disorders"],"prefix":"10.1007","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6933-5675","authenticated-orcid":false,"given":"Matteo","family":"Carpi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6700-7491","authenticated-orcid":false,"given":"Nicola Biagio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2845-1332","authenticated-orcid":false,"given":"Claudio","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"issue":"1","key":"2096_CR1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1073\/pnas.95.1.322","volume":"95","author":"L de Lecea","year":"1998","unstructured":"de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A. 1998;95(1):322\u20137. https:\/\/doi.org\/10.1073\/pnas.95.1.322.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2096_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","volume":"92","author":"T Sakurai","year":"1998","unstructured":"Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573\u201385. https:\/\/doi.org\/10.1016\/S0092-8674(00)80949-6.","journal-title":"Cell"},{"issue":"23","key":"2096_CR3","doi-asserted-by":"publisher","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","volume":"18","author":"C Peyron","year":"1998","unstructured":"Peyron C, Tighe DK, Van Den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18(23):9996\u201310015. https:\/\/doi.org\/10.1523\/JNEUROSCI.18-23-09996.1998.","journal-title":"J Neurosci"},{"issue":"2","key":"2096_CR4","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1073\/pnas.96.2.748","volume":"96","author":"Y Date","year":"1999","unstructured":"Date Y, Ueta Y, Yamashita H, et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci U S A. 1999;96(2):748\u201353. https:\/\/doi.org\/10.1073\/pnas.96.2.748.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2096_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1749-6632.2010.05513.x","volume":"1200","author":"T Sakurai","year":"2010","unstructured":"Sakurai T, Mieda M, Tsujino N. The orexin system: roles in sleep\/wake regulation: orexin and sleep\/wake state. Ann N Y Acad Sci. 2010;1200(1):149\u201361. https:\/\/doi.org\/10.1111\/j.1749-6632.2010.05513.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"2096_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/med.21326","volume":"35","author":"Q Chen","year":"2015","unstructured":"Chen Q, de Lecea L, Hu Z, Gao D. The hypocretin\/orexin system: an increasingly important role in neuropsychiatry: the hypocretin\/orexin system in neuropsychiatry. Med Res Rev. 2015;35(1):152\u201397. https:\/\/doi.org\/10.1002\/med.21326.","journal-title":"Med Res Rev"},{"issue":"10","key":"2096_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.tins.2006.08.002","volume":"29","author":"GC Harris","year":"2006","unstructured":"Harris GC, Aston-Jones G. Arousal and reward: a dichotomy in orexin function. Trends Neurosci. 2006;29(10):571\u20137. https:\/\/doi.org\/10.1016\/j.tins.2006.08.002.","journal-title":"Trends Neurosci"},{"issue":"7058","key":"2096_CR8","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nature04071","volume":"437","author":"GC Harris","year":"2005","unstructured":"Harris GC, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature. 2005;437(7058):556\u20139. https:\/\/doi.org\/10.1038\/nature04071.","journal-title":"Nature"},{"issue":"11","key":"2096_CR9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrn3837","volume":"15","author":"T Sakurai","year":"2014","unstructured":"Sakurai T. The role of orexin in motivated behaviours. Nat Rev Neurosci. 2014;15(11):719\u201331. https:\/\/doi.org\/10.1038\/nrn3837.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"2096_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1124\/pr.109.001321","volume":"61","author":"N Tsujino","year":"2009","unstructured":"Tsujino N, Sakurai T. Orexin\/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev. 2009;61(2):162\u201376. https:\/\/doi.org\/10.1124\/pr.109.001321.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"2096_CR11","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/ncomms2461","volume":"4","author":"AM Blouin","year":"2013","unstructured":"Blouin AM, Fried I, Wilson CL, et al. Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction. Nat Commun. 2013;4(1):1547. https:\/\/doi.org\/10.1038\/ncomms2461.","journal-title":"Nat Commun"},{"key":"2096_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fphar.2014.00016","volume":"5","author":"L de Lecea","year":"2014","unstructured":"de Lecea L, Huerta R. Hypocretin (orexin) regulation of sleep-to-wake transitions. Front Pharmacol. 2014;5:16. https:\/\/doi.org\/10.3389\/fphar.2014.00016.","journal-title":"Front Pharmacol"},{"issue":"7","key":"2096_CR13","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1523\/JNEUROSCI.22-07-02862.2002","volume":"22","author":"S Burlet","year":"2002","unstructured":"Burlet S, Tyler CJ, Leonard CS. Direct and indirect excitation of laterodorsal tegmental neurons by hypocretin\/orexin peptides: implications for wakefulness and narcolepsy. J Neurosci. 2002;22(7):2862\u201372. https:\/\/doi.org\/10.1523\/JNEUROSCI.22-07-02862.2002.","journal-title":"J Neurosci"},{"issue":"17","key":"2096_CR14","doi-asserted-by":"publisher","first-page":"7754","DOI":"10.1523\/JNEUROSCI.22-17-07754.2002","volume":"22","author":"M Wu","year":"2002","unstructured":"Wu M, Zhang Z, Leranth C, Xu C, Van Den Pol AN, Alreja M. Hypocretin increases impulse flow in the septohippocampal GABAergic pathway: implications for arousal via a mechanism of hippocampal disinhibition. J Neurosci. 2002;22(17):7754\u201365. https:\/\/doi.org\/10.1523\/JNEUROSCI.22-17-07754.2002.","journal-title":"J Neurosci"},{"issue":"6","key":"2096_CR15","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.neuron.2010.11.032","volume":"68","author":"CB Saper","year":"2010","unstructured":"Saper CB, Fuller PM, Pedersen NP, Lu J, Scammell TE. Sleep state switching. Neuron. 2010;68(6):1023\u201342. https:\/\/doi.org\/10.1016\/j.neuron.2010.11.032.","journal-title":"Neuron"},{"issue":"3","key":"2096_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/s0028-3908(00)00178-7","volume":"40","author":"RE Brown","year":"2001","unstructured":"Brown RE, Sergeeva O, Eriksson KS, Haas HL. Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat. Neuropharmacology. 2001;40(3):457\u20139. https:\/\/doi.org\/10.1016\/s0028-3908(00)00178-7.","journal-title":"Neuropharmacology"},{"issue":"1","key":"2096_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1113\/jphysiol.2002.017426","volume":"541","author":"AN van den Pol","year":"2002","unstructured":"van den Pol AN, Ghosh PK, Liu R, Li Y, Aghajanian GK, Gao X. Hypocretin (orexin) enhances neuron activity and cell synchrony in developing mouse GFP-expressing locus coeruleus. J Physiol. 2002;541(1):169\u201385. https:\/\/doi.org\/10.1113\/jphysiol.2002.017426.","journal-title":"J Physiol"},{"issue":"2","key":"2096_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0306-4522(01)00512-7","volume":"108","author":"E Eggermann","year":"2001","unstructured":"Eggermann E, Serafin M, Bayer L, et al. Orexins\/hypocretins excite basal forebrain cholinergic neurones. Neuroscience. 2001;108(2):177\u201381. https:\/\/doi.org\/10.1016\/S0306-4522(01)00512-7.","journal-title":"Neuroscience"},{"issue":"28","key":"2096_CR19","doi-asserted-by":"publisher","first-page":"6716","DOI":"10.1523\/JNEUROSCI.1887-05.2005","volume":"25","author":"MG Lee","year":"2005","unstructured":"Lee MG, Hassani OK, Jones BE. Discharge of identified orexin\/hypocretin neurons across the sleep-waking cycle. J Neurosci Off J Soc Neurosci. 2005;25(28):6716\u201320. https:\/\/doi.org\/10.1523\/JNEUROSCI.1887-05.2005.","journal-title":"J Neurosci Off J Soc Neurosci."},{"issue":"5","key":"2096_CR20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.neuron.2005.04.035","volume":"46","author":"BY Mileykovskiy","year":"2005","unstructured":"Mileykovskiy BY, Kiyashchenko LI, Siegel JM. Behavioral correlates of activity in identified hypocretin\/orexin neurons. Neuron. 2005;46(5):787\u201398. https:\/\/doi.org\/10.1016\/j.neuron.2005.04.035.","journal-title":"Neuron"},{"issue":"9197","key":"2096_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","volume":"355","author":"S Nishino","year":"2000","unstructured":"Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. The Lancet. 2000;355(9197):39\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(99)05582-8.","journal-title":"The Lancet"},{"issue":"4","key":"2096_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa2301940","volume":"389","author":"Y Dauvilliers","year":"2023","unstructured":"Dauvilliers Y, Mignot E, Del R\u00edo VR, et al. Oral orexin receptor 2 agonist in narcolepsy type 1. N Engl J Med. 2023;389(4):309\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2301940.","journal-title":"N Engl J Med"},{"key":"2096_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13825","author":"L Palagini","year":"2023","unstructured":"Palagini L, Geoffroy PA, Balestrieri M, et al. Current models of insomnia disorder: a theoretical review on the potential role of the orexinergic pathway with implications for insomnia treatment. J Sleep Res. 2023. https:\/\/doi.org\/10.1111\/jsr.13825.","journal-title":"J Sleep Res"},{"key":"2096_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jsr.13665","volume":"31","author":"F Pizza","year":"2022","unstructured":"Pizza F, Barateau L, Dauvilliers Y, Plazzi G. The orexin story, sleep and sleep disturbances. J Sleep Res. 2022;31:4. https:\/\/doi.org\/10.1111\/jsr.13665.","journal-title":"J Sleep Res"},{"key":"2096_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.smrv.2016.09.004","volume":"35","author":"A Kuriyama","year":"2017","unstructured":"Kuriyama A, Tabata H. Suvorexant for the treatment of primary insomnia: a systematic review and meta-analysis. Sleep Med Rev. 2017;35:1\u20137. https:\/\/doi.org\/10.1016\/j.smrv.2016.09.004.","journal-title":"Sleep Med Rev"},{"key":"2096_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jpsychires.2020.05.025","volume":"128","author":"T Kishi","year":"2020","unstructured":"Kishi T, Nomura I, Matsuda Y, et al. Lemborexant vs suvorexant for insomnia: a systematic review and network meta-analysis. J Psychiatr Res. 2020;128:68\u201374. https:\/\/doi.org\/10.1016\/j.jpsychires.2020.05.025.","journal-title":"J Psychiatr Res"},{"issue":"2","key":"2096_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","volume":"21","author":"E Mignot","year":"2022","unstructured":"Mignot E, Mayleben D, Fietze I, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022;21(2):125\u201339. https:\/\/doi.org\/10.1016\/S1474-4422(21)00436-1.","journal-title":"Lancet Neurol"},{"key":"2096_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/sleep\/zsy025","volume":"41","author":"M Olsson","year":"2018","unstructured":"Olsson M, \u00c4rlig J, Hedner J, Blennow K, Zetterberg H. Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimer\u2019s disease. Sleep. 2018;41:5. https:\/\/doi.org\/10.1093\/sleep\/zsy025.","journal-title":"Sleep"},{"key":"2096_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.neulet.2015.01.067","volume":"590","author":"R Mehta","year":"2015","unstructured":"Mehta R, Khanday MA, Mallick BN. REM sleep loss associated changes in orexin-A levels in discrete brain areas in rats. Neurosci Lett. 2015;590:62\u20137. https:\/\/doi.org\/10.1016\/j.neulet.2015.01.067.","journal-title":"Neurosci Lett"},{"issue":"17","key":"2096_CR30","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1523\/JNEUROSCI.6506-10.2011","volume":"31","author":"M Mieda","year":"2011","unstructured":"Mieda M, Hasegawa E, Kisanuki YY, Sinton CM, Yanagisawa M, Sakurai T. Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. J Neurosci Off J Soc Neurosci. 2011;31(17):6518\u201326. https:\/\/doi.org\/10.1523\/JNEUROSCI.6506-10.2011.","journal-title":"J Neurosci Off J Soc Neurosci."},{"issue":"2\u20133","key":"2096_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1054\/npep.2002.0892","volume":"36","author":"L de Lecea","year":"2002","unstructured":"de Lecea L, Sutcliffe JG, Fabre V. Hypocretins\/orexins as integrators of physiological information: lessons from mutant animals. Neuropeptides. 2002;36(2\u20133):85\u201395. https:\/\/doi.org\/10.1054\/npep.2002.0892.","journal-title":"Neuropeptides"},{"issue":"1","key":"2096_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1124\/jpet.109.152009","volume":"330","author":"C Dugovic","year":"2009","unstructured":"Dugovic C, Shelton JE, Aluisio LE, et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther. 2009;330(1):142\u201351. https:\/\/doi.org\/10.1124\/jpet.109.152009.","journal-title":"J Pharmacol Exp Ther"},{"issue":"36","key":"2096_CR33","doi-asserted-by":"publisher","first-page":"14549","DOI":"10.1523\/JNEUROSCI.1130-13.2013","volume":"33","author":"S Soya","year":"2013","unstructured":"Soya S, Shoji H, Hasegawa E, et al. Orexin receptor-1 in the locus coeruleus plays an important role in cue-dependent fear memory consolidation. J Neurosci Off J Soc Neurosci. 2013;33(36):14549\u201357. https:\/\/doi.org\/10.1523\/JNEUROSCI.1130-13.2013.","journal-title":"J Neurosci Off J Soc Neurosci."},{"issue":"1","key":"2096_CR34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/cne.1190","volume":"435","author":"JN Marcus","year":"2001","unstructured":"Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol. 2001;435(1):6\u201325. https:\/\/doi.org\/10.1002\/cne.1190.","journal-title":"J Comp Neurol"},{"key":"2096_CR35","doi-asserted-by":"publisher","first-page":"27147","DOI":"10.1038\/srep27147","volume":"6","author":"AL Gotter","year":"2016","unstructured":"Gotter AL, Forman MS, Harrell CM, et al. Orexin 2 receptor antagonism is sufficient to promote NREM and REM sleep from mouse to man. Sci Rep. 2016;6:27147. https:\/\/doi.org\/10.1038\/srep27147.","journal-title":"Sci Rep"},{"key":"2096_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2020.101332","volume":"53","author":"JW Clark","year":"2020","unstructured":"Clark JW, Brian ML, Drummond SPA, Hoyer D, Jacobson LH. Effects of orexin receptor antagonism on human sleep architecture: a systematic review. Sleep Med Rev. 2020;53: 101332. https:\/\/doi.org\/10.1016\/j.smrv.2020.101332.","journal-title":"Sleep Med Rev"},{"key":"2096_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/NSS.S201994","volume":"15","author":"MP Mogavero","year":"2023","unstructured":"Mogavero MP, Silvani A, Lanza G, DelRosso LM, Ferini-Strambi L, Ferri R. Targeting orexin receptors for the treatment of insomnia: from physiological mechanisms to current clinical evidence and recommendations. Nat Sci Sleep. 2023;15:17\u201338. https:\/\/doi.org\/10.2147\/NSS.S201994.","journal-title":"Nat Sci Sleep."},{"issue":"08","key":"2096_CR38","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.5664\/jcsm.7282","volume":"14","author":"K Janto","year":"2018","unstructured":"Janto K, Prichard JR, Pusalavidyasagar S. An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics. J Clin Sleep Med. 2018;14(08):1399\u2013408. https:\/\/doi.org\/10.5664\/jcsm.7282.","journal-title":"J Clin Sleep Med"},{"issue":"4","key":"2096_CR39","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/ejn.15077","volume":"53","author":"C Berteotti","year":"2021","unstructured":"Berteotti C, Liguori C, Pace M. Dysregulation of the orexin\/hypocretin system is not limited to narcolepsy but has far-reaching implications for neurological disorders. Eur J Neurosci. 2021;53(4):1136\u201354. https:\/\/doi.org\/10.1111\/ejn.15077.","journal-title":"Eur J Neurosci"},{"key":"2096_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000514955","volume-title":"Frontiers of neurology and neuroscience","author":"T Sakurai","year":"2021","unstructured":"Sakurai T, Saito YC, Yanagisawa M. Interaction between orexin neurons and monoaminergic systems. In: Steiner MA, Yanagisawa M, Clozel M, editors. Frontiers of neurology and neuroscience, vol. 45. Berlin: Karger AG; 2021. p. 11\u201321. https:\/\/doi.org\/10.1159\/000514955."},{"key":"2096_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2017.00010","author":"I Villano","year":"2017","unstructured":"Villano I, Messina A, Valenzano A, et al. Basal forebrain cholinergic system and orexin neurons: effects on attention. Front Behav Neurosci. 2017. https:\/\/doi.org\/10.3389\/fnbeh.2017.00010.","journal-title":"Front Behav Neurosci"},{"key":"2096_CR42","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000514967","volume-title":"Frontiers of neurology and neuroscience","author":"Y Dauvilliers","year":"2021","unstructured":"Dauvilliers Y. Hypocretin\/orexin, sleep and Alzheimer\u2019s disease. In: Steiner MA, Yanagisawa M, Clozel M, editors. Frontiers of neurology and neuroscience, vol. 45. Berlin: Karger AG; 2021. p. 139\u201349. https:\/\/doi.org\/10.1159\/000514967."},{"key":"2096_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2021.136247","volume":"765","author":"F Gao","year":"2021","unstructured":"Gao F, Liu T, Tuo M, Chi S. The role of orexin in Alzheimer disease: from sleep-wake disturbance to therapeutic target. Neurosci Lett. 2021;765: 136247. https:\/\/doi.org\/10.1016\/j.neulet.2021.136247.","journal-title":"Neurosci Lett"},{"key":"2096_CR44","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/7854_2016_50","volume":"33","author":"C Liguori","year":"2017","unstructured":"Liguori C. Orexin and Alzheimer\u2019s disease. Curr Top Behav Neurosci. 2017;33:305\u201322. https:\/\/doi.org\/10.1007\/7854_2016_50.","journal-title":"Curr Top Behav Neurosci"},{"issue":"8","key":"2096_CR45","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.tins.2016.05.002","volume":"39","author":"BA Mander","year":"2016","unstructured":"Mander BA, Winer JR, Jagust WJ, Walker MP. Sleep: a novel mechanistic pathway, biomarker, and treatment target in the pathology of Alzheimer\u2019s disease? Trends Neurosci. 2016;39(8):552\u201366. https:\/\/doi.org\/10.1016\/j.tins.2016.05.002.","journal-title":"Trends Neurosci"},{"issue":"5955","key":"2096_CR46","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1126\/science.1180962","volume":"326","author":"JE Kang","year":"2009","unstructured":"Kang JE, Lim MM, Bateman RJ, et al. Amyloid-\u03b2 dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005\u20137. https:\/\/doi.org\/10.1126\/science.1180962.","journal-title":"Science"},{"issue":"13","key":"2096_CR47","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1084\/jem.20141788","volume":"211","author":"JH Roh","year":"2014","unstructured":"Roh JH, Jiang H, Finn MB, et al. Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer\u2019s disease. J Exp Med. 2014;211(13):2487\u201396. https:\/\/doi.org\/10.1084\/jem.20141788.","journal-title":"J Exp Med"},{"issue":"1","key":"2096_CR48","doi-asserted-by":"publisher","first-page":"36035","DOI":"10.1038\/srep36035","volume":"6","author":"Z Ma","year":"2016","unstructured":"Ma Z, Jiang W, Zhang EE. Orexin signaling regulates both the hippocampal clock and the circadian oscillation of Alzheimer\u2019s disease-risk genes. Sci Rep. 2016;6(1):36035. https:\/\/doi.org\/10.1038\/srep36035.","journal-title":"Sci Rep"},{"issue":"4","key":"2096_CR49","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement J Alzheimers Assoc."},{"key":"2096_CR50","doi-asserted-by":"publisher","unstructured":"2024 Alzheimer\u2019s disease facts and figures. Alzheimers Dement J Alzheimers Assoc. 2024;20(5):3708\u20133821. https:\/\/doi.org\/10.1002\/alz.13809","DOI":"10.1002\/alz.13809"},{"issue":"1","key":"2096_CR51","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","volume":"18","author":"E Nichols","year":"2019","unstructured":"Nichols E, Szoeke CEI, Vollset SE, et al. Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(1):88\u2013106. https:\/\/doi.org\/10.1016\/S1474-4422(18)30403-4.","journal-title":"Lancet Neurol"},{"issue":"4","key":"2096_CR52","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41582-024-00940-4","volume":"20","author":"AD Korczyn","year":"2024","unstructured":"Korczyn AD, Grinberg LT. Is Alzheimer disease a disease? Nat Rev Neurol. 2024;20(4):245\u201351. https:\/\/doi.org\/10.1038\/s41582-024-00940-4.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"2096_CR53","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/jgs.16027","volume":"67","author":"S Gao","year":"2019","unstructured":"Gao S, Burney HN, Callahan CM, Purnell CE, Hendrie HC. Incidence of dementia and Alzheimer disease over time: a meta-analysis. J Am Geriatr Soc. 2019;67(7):1361\u20139. https:\/\/doi.org\/10.1111\/jgs.16027.","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"2096_CR54","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1001\/jamaneurol.2022.1732","volume":"79","author":"ES Musiek","year":"2022","unstructured":"Musiek ES, Ju YES. Targeting sleep and circadian function in the prevention of Alzheimer disease. JAMA Neurol. 2022;79(9):835. https:\/\/doi.org\/10.1001\/jamaneurol.2022.1732.","journal-title":"JAMA Neurol"},{"key":"2096_CR55","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3389\/fphar.2019.00695","volume":"10","author":"S Cordone","year":"2019","unstructured":"Cordone S, Annarumma L, Rossini PM, De Gennaro L. Sleep and beta-amyloid deposition in Alzheimer disease: insights on mechanisms and possible innovative treatments. Front Pharmacol. 2019;10:695. https:\/\/doi.org\/10.3389\/fphar.2019.00695.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2096_CR56","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41398-022-01897-y","volume":"12","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Ren R, Yang L, et al. Sleep in Alzheimer\u2019s disease: a systematic review and meta-analysis of polysomnographic findings. Transl Psychiatry. 2022;12(1):136. https:\/\/doi.org\/10.1038\/s41398-022-01897-y.","journal-title":"Transl Psychiatry"},{"key":"2096_CR57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.smrv.2014.03.007","volume":"19","author":"L Peter-Derex","year":"2015","unstructured":"Peter-Derex L, Yammine P, Bastuji H, Croisile B. Sleep and Alzheimer\u2019s disease. Sleep Med Rev. 2015;19:29\u201338. https:\/\/doi.org\/10.1016\/j.smrv.2014.03.007.","journal-title":"Sleep Med Rev"},{"key":"2096_CR58","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/sleep\/zsz251","volume":"43","author":"L Webster","year":"2020","unstructured":"Webster L, Costafreda Gonzalez S, Stringer A, et al. Measuring the prevalence of sleep disturbances in people with dementia living in care homes: a systematic review and meta-analysis. Sleep. 2020;43:4. https:\/\/doi.org\/10.1093\/sleep\/zsz251.","journal-title":"Sleep"},{"key":"2096_CR59","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jad.2015.09.069","volume":"190","author":"QF Zhao","year":"2016","unstructured":"Zhao QF, Tan L, Wang HF, et al. The prevalence of neuropsychiatric symptoms in Alzheimer\u2019s disease: systematic review and meta-analysis. J Affect Disord. 2016;190:264\u201371. https:\/\/doi.org\/10.1016\/j.jad.2015.09.069.","journal-title":"J Affect Disord"},{"issue":"MAY","key":"2096_CR60","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3389\/fnins.2018.00330","volume":"12","author":"A Brzecka","year":"2018","unstructured":"Brzecka A, Leszek J, Ashraf GM, et al. Sleep disorders associated with Alzheimer\u2019s disease: a perspective. Front Neurosci. 2018;12(MAY):330. https:\/\/doi.org\/10.3389\/fnins.2018.00330.","journal-title":"Front Neurosci"},{"issue":"3","key":"2096_CR61","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1038\/emm.2014.121","volume":"47","author":"ES Musiek","year":"2015","unstructured":"Musiek ES, Xiong DD, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis of Alzheimer Disease. Exp Mol Med. 2015;47(3):e148\u2013e148. https:\/\/doi.org\/10.1038\/emm.2014.121.","journal-title":"Exp Mol Med"},{"issue":"3","key":"2096_CR62","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(18)30461-7","volume":"18","author":"Y Leng","year":"2019","unstructured":"Leng Y, Musiek ES, Hu K, Cappuccio FP, Yaffe K. Association between circadian rhythms and neurodegenerative diseases. Lancet Neurol. 2019;18(3):307\u201318. https:\/\/doi.org\/10.1016\/S1474-4422(18)30461-7.","journal-title":"Lancet Neurol"},{"issue":"12","key":"2096_CR63","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrneurol.2014.206","volume":"10","author":"A Videnovic","year":"2014","unstructured":"Videnovic A, Lazar AS, Barker RA, Overeem S. \u2019The clocks that time us\u2019\u2014circadian rhythms in neurodegenerative disorders. Nat Rev Neurol. 2014;10(12):683\u201393. https:\/\/doi.org\/10.1038\/nrneurol.2014.206.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2096_CR64","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-019-0478-5","volume":"45","author":"C Wang","year":"2020","unstructured":"Wang C, Holtzman DM. Bidirectional relationship between sleep and Alzheimer\u2019s disease: role of amyloid, tau, and other factors. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2020;45(1):104\u201320. https:\/\/doi.org\/10.1038\/s41386-019-0478-5.","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol."},{"key":"2096_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105031","volume":"144","author":"BP Lucey","year":"2020","unstructured":"Lucey BP. It\u2019s complicated: the relationship between sleep and Alzheimer\u2019s disease in humans. Neurobiol Dis. 2020;144: 105031. https:\/\/doi.org\/10.1016\/j.nbd.2020.105031.","journal-title":"Neurobiol Dis"},{"issue":"4","key":"2096_CR66","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.sleep.2004.12.005","volume":"6","author":"M Moran","year":"2005","unstructured":"Moran M, Lynch CA, Walsh C, Coen R, Coakley D, Lawlor BA. Sleep disturbance in mild to moderate Alzheimer\u2019s disease. Sleep Med. 2005;6(4):347\u201352. https:\/\/doi.org\/10.1016\/j.sleep.2004.12.005.","journal-title":"Sleep Med"},{"issue":"5","key":"2096_CR67","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2017.4719","volume":"75","author":"ES Musiek","year":"2018","unstructured":"Musiek ES, Bhimasani M, Zangrilli MA, Morris JC, Holtzman DM, Ju YES. Circadian rest-activity pattern changes in aging and preclinical Alzheimer disease. JAMA Neurol. 2018;75(5):582. https:\/\/doi.org\/10.1001\/jamaneurol.2017.4719.","journal-title":"JAMA Neurol"},{"key":"2096_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.115760","volume":"333","author":"Y Xiong","year":"2024","unstructured":"Xiong Y, Tvedt J, \u00c5kerstedt T, Cadar D, Wang HX. Impact of sleep duration and sleep disturbances on the incidence of dementia and Alzheimer\u2019s disease: a 10-year follow-up study. Psychiatry Res. 2024;333: 115760. https:\/\/doi.org\/10.1016\/j.psychres.2024.115760.","journal-title":"Psychiatry Res"},{"key":"2096_CR69","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12380-7","author":"S Wang","year":"2024","unstructured":"Wang S, Zheng X, Huang J, Liu J, Li C, Shang H. Sleep characteristics and risk of Alzheimer\u2019s disease: a systematic review and meta-analysis of longitudinal studies. J Neurol. 2024. https:\/\/doi.org\/10.1007\/s00415-024-12380-7.","journal-title":"J Neurol"},{"issue":"1","key":"2096_CR70","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3233\/JAD-230933","volume":"97","author":"M Carpi","year":"2024","unstructured":"Carpi M, Fernandes M, Mercuri NB, Liguori C. Sleep biomarkers for predicting cognitive decline and Alzheimer\u2019s disease: a systematic review of longitudinal studies. J Alzheimers Dis JAD. 2024;97(1):121\u201343. https:\/\/doi.org\/10.3233\/JAD-230933.","journal-title":"J Alzheimers Dis JAD."},{"key":"2096_CR71","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.smrv.2017.06.010","volume":"40","author":"L Shi","year":"2018","unstructured":"Shi L, Chen SJ, Ma MY, et al. Sleep disturbances increase the risk of dementia: a systematic review and meta-analysis. Sleep Med Rev. 2018;40:4\u201316. https:\/\/doi.org\/10.1016\/j.smrv.2017.06.010.","journal-title":"Sleep Med Rev"},{"issue":"9","key":"2096_CR72","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1093\/brain\/awab272","volume":"144","author":"BP Lucey","year":"2021","unstructured":"Lucey BP, Wisch J, Boerwinkle AH, et al. Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimer\u2019s disease. Brain J Neurol. 2021;144(9):2852\u201362. https:\/\/doi.org\/10.1093\/brain\/awab272.","journal-title":"Brain J Neurol."},{"issue":"10","key":"2096_CR73","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaneurol.2017.2180","volume":"74","author":"Y Leng","year":"2017","unstructured":"Leng Y, McEvoy CT, Allen IE, Yaffe K. Association of sleep-disordered breathing with cognitive function and risk of cognitive impairment: a systematic review and meta-analysis. JAMA Neurol. 2017;74(10):1237. https:\/\/doi.org\/10.1001\/jamaneurol.2017.2180.","journal-title":"JAMA Neurol"},{"issue":"3","key":"2096_CR74","doi-asserted-by":"publisher","first-page":"411","DOI":"10.5665\/sleep.4500","volume":"38","author":"Y Song","year":"2015","unstructured":"Song Y, Blackwell T, Yaffe K, Ancoli-Israel S, Redline S, Stone KL. Relationships between sleep stages and changes in cognitive function in older men: the MrOS Sleep Study. Sleep. 2015;38(3):411\u201321. https:\/\/doi.org\/10.5665\/sleep.4500.","journal-title":"Sleep"},{"issue":"3","key":"2096_CR75","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nn.3324","volume":"16","author":"BA Mander","year":"2013","unstructured":"Mander BA, Rao V, Lu B, et al. Prefrontal atrophy, disrupted NREM slow waves and impaired hippocampal-dependent memory in aging. Nat Neurosci. 2013;16(3):357\u201364. https:\/\/doi.org\/10.1038\/nn.3324.","journal-title":"Nat Neurosci"},{"issue":"2","key":"2096_CR76","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/jsr.12108","volume":"23","author":"M Lafortune","year":"2014","unstructured":"Lafortune M, Gagnon JF, Martin N, et al. Sleep spindles and rapid eye movement sleep as predictors of next morning cognitive performance in healthy middle-aged and older participants. J Sleep Res. 2014;23(2):159\u201367. https:\/\/doi.org\/10.1111\/jsr.12108.","journal-title":"J Sleep Res"},{"issue":"2","key":"2096_CR77","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nrn2762","volume":"11","author":"S Diekelmann","year":"2010","unstructured":"Diekelmann S, Born J. The memory function of sleep. Nat Rev Neurosci. 2010;11(2):114\u201326. https:\/\/doi.org\/10.1038\/nrn2762.","journal-title":"Nat Rev Neurosci"},{"issue":"32","key":"2096_CR78","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1523\/JNEUROSCI.0503-19.2019","volume":"39","author":"JR Winer","year":"2019","unstructured":"Winer JR, Mander BA, Helfrich RF, et al. Sleep as a potential biomarker of tau and beta-amyloid burden in the human brain. J Neurosci Off J Soc Neurosci. 2019;39(32):6315\u201324. https:\/\/doi.org\/10.1523\/JNEUROSCI.0503-19.2019.","journal-title":"J Neurosci Off J Soc Neurosci."},{"key":"2096_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cophys.2019.10.020","volume":"15","author":"NL Hauglund","year":"2020","unstructured":"Hauglund NL, Pavan C, Nedergaard M. Cleaning the sleeping brain\u2014the potential restorative function of the glymphatic system. Curr Opin Physiol. 2020;15:1\u20136. https:\/\/doi.org\/10.1016\/j.cophys.2019.10.020.","journal-title":"Curr Opin Physiol."},{"key":"2096_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2023.111899","volume":"217","author":"K Astara","year":"2024","unstructured":"Astara K, Tsimpolis A, Kalafatakis K, et al. Sleep disorders and Alzheimer\u2019s disease pathophysiology: the role of the glymphatic system. A scoping review. Mech Ageing Dev. 2024;217: 111899. https:\/\/doi.org\/10.1016\/j.mad.2023.111899.","journal-title":"Mech Ageing Dev"},{"key":"2096_CR81","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1212\/WNL.0000000000201300","volume":"99","author":"K Kamagata","year":"2022","unstructured":"Kamagata K, Andica C, Takabayashi K, et al. Association of MRI indices of glymphatic system with amyloid deposition and cognition in mild cognitive impairment and Alzheimer disease. Neurology. 2022;99:24. https:\/\/doi.org\/10.1212\/WNL.0000000000201300.","journal-title":"Neurology"},{"issue":"7","key":"2096_CR82","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/nn.4035","volume":"18","author":"BA Mander","year":"2015","unstructured":"Mander BA, Marks SM, Vogel JW, et al. \u03b2-amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation. Nat Neurosci. 2015;18(7):1051\u20137. https:\/\/doi.org\/10.1038\/nn.4035.","journal-title":"Nat Neurosci"},{"issue":"Pt 10","key":"2096_CR83","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/brain\/awu222","volume":"137","author":"ASP Lim","year":"2014","unstructured":"Lim ASP, Ellison BA, Wang JL, et al. Sleep is related to neuron numbers in the ventrolateral preoptic\/intermediate nucleus in older adults with and without Alzheimer\u2019s disease. Brain J Neurol. 2014;137(Pt 10):2847\u201361. https:\/\/doi.org\/10.1093\/brain\/awu222.","journal-title":"Brain J Neurol."},{"key":"2096_CR84","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neubiorev.2019.07.019","volume":"105","author":"J Van Erum","year":"2019","unstructured":"Van Erum J, Van Dam D, De Deyn PP. Alzheimer\u2019s disease: Neurotransmitters of the sleep-wake cycle. Neurosci Biobehav Rev. 2019;105:72\u201380. https:\/\/doi.org\/10.1016\/j.neubiorev.2019.07.019.","journal-title":"Neurosci Biobehav Rev"},{"issue":"8","key":"2096_CR85","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.neurobiolaging.2011.03.014","volume":"33","author":"R Fronczek","year":"2012","unstructured":"Fronczek R, van Geest S, Fr\u00f6lich M, et al. Hypocretin (orexin) loss in Alzheimer\u2019s disease. Neurobiol Aging. 2012;33(8):1642\u201350. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.03.014.","journal-title":"Neurobiol Aging"},{"issue":"10","key":"2096_CR86","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jalz.2019.06.3916","volume":"15","author":"JY Oh","year":"2019","unstructured":"Oh JY, Eser RA, Ehrenberg AJ, et al. Profound degeneration of wake-promoting neurons in Alzheimer\u2019s disease. Alzheimers Dement. 2019;15(10):1253\u201363. https:\/\/doi.org\/10.1016\/j.jalz.2019.06.3916.","journal-title":"Alzheimers Dement"},{"key":"2096_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2021.101541","volume":"60","author":"CH Lew","year":"2021","unstructured":"Lew CH, Petersen C, Neylan TC, Grinberg LT. Tau-driven degeneration of sleep- and wake-regulating neurons in Alzheimer\u2019s disease. Sleep Med Rev. 2021;60: 101541. https:\/\/doi.org\/10.1016\/j.smrv.2021.101541.","journal-title":"Sleep Med Rev"},{"issue":"12","key":"2096_CR88","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1001\/jamaneurol.2014.2510","volume":"71","author":"C Liguori","year":"2014","unstructured":"Liguori C, Romigi A, Nuccetelli M, et al. Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol. 2014;71(12):1498\u2013505. https:\/\/doi.org\/10.1001\/jamaneurol.2014.2510.","journal-title":"JAMA Neurol"},{"key":"2096_CR89","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.neurobiolaging.2016.01.007","volume":"40","author":"C Liguori","year":"2016","unstructured":"Liguori C, Nuccetelli M, Izzi F, et al. Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer\u2019s disease. Neurobiol Aging. 2016;40:120\u20136. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.01.007.","journal-title":"Neurobiol Aging"},{"key":"2096_CR90","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fnagi.2014.00119","volume":"6","author":"YA Dauvilliers","year":"2014","unstructured":"Dauvilliers YA, Lehmann S, Jaussent I, Gabelle A. Hypocretin and brain \u03b2-amyloid peptide interactions in cognitive disorders and narcolepsy. Front Aging Neurosci. 2014;6:119. https:\/\/doi.org\/10.3389\/fnagi.2014.00119.","journal-title":"Front Aging Neurosci."},{"key":"2096_CR91","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.neurobiolaging.2017.01.011","volume":"53","author":"A Gabelle","year":"2017","unstructured":"Gabelle A, Jaussent I, Hirtz C, et al. Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process. Neurobiol Aging. 2017;53:59\u201366. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.01.011.","journal-title":"Neurobiol Aging"},{"key":"2096_CR92","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.sleep.2021.07.007","volume":"85","author":"SP Treu","year":"2021","unstructured":"Treu SP, Plante DT. Cerebrospinal fluid orexin in Alzheimer\u2019s disease: a systematic review and meta-analysis. Sleep Med. 2021;85:230\u20138. https:\/\/doi.org\/10.1016\/j.sleep.2021.07.007.","journal-title":"Sleep Med"},{"key":"2096_CR93","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.sleep.2019.01.003","volume":"56","author":"C Liguori","year":"2019","unstructured":"Liguori C, Mercuri NB, Nuccetelli M, et al. Obstructive sleep apnea may induce orexinergic system and cerebral \u03b2-amyloid metabolism dysregulation: is it a further proof for Alzheimer\u2019s disease risk? Sleep Med. 2019;56:171\u20136. https:\/\/doi.org\/10.1016\/j.sleep.2019.01.003.","journal-title":"Sleep Med"},{"issue":"6","key":"2096_CR94","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.5665\/sleep.5846","volume":"39","author":"RS Osorio","year":"2016","unstructured":"Osorio RS, Ducca EL, Wohlleber ME, et al. Orexin-A is associated with increases in cerebrospinal fluid phosphorylated-tau in cognitively normal elderly subjects. Sleep. 2016;39(6):1253\u201360. https:\/\/doi.org\/10.5665\/sleep.5846.","journal-title":"Sleep"},{"issue":"10","key":"2096_CR95","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2174\/156720512804142840","volume":"9","author":"D Slats","year":"2012","unstructured":"Slats D, Claassen J, Jan Lammers G, Melis R, Verbeek M, Overeem S. Association between hypocretin-1 and amyloid-beta;42 cerebrospinal fluid levels in alzheimer\u2019s disease and healthy controls. Curr Alzheimer Res. 2012;9(10):1119\u201325. https:\/\/doi.org\/10.2174\/156720512804142840.","journal-title":"Curr Alzheimer Res"},{"issue":"2","key":"2096_CR96","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3233\/JAD-191124","volume":"74","author":"C Liguori","year":"2020","unstructured":"Liguori C, Spanetta M, Izzi F, et al. Sleep-wake cycle in Alzheimer\u2019s disease is associated with tau pathology and orexin dysregulation. J Alzheimers Dis JAD. 2020;74(2):501\u20138. https:\/\/doi.org\/10.3233\/JAD-191124.","journal-title":"J Alzheimers Dis JAD."},{"issue":"1","key":"2096_CR97","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/ana.25373","volume":"85","author":"A Gabelle","year":"2019","unstructured":"Gabelle A, Jaussent I, Bouall\u00e8gue FB, et al. Reduced brain amyloid burden in elderly patients with narcolepsy type 1. Ann Neurol. 2019;85(1):74\u201383. https:\/\/doi.org\/10.1002\/ana.25373.","journal-title":"Ann Neurol"},{"issue":"1","key":"2096_CR98","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/ana.25117","volume":"83","author":"BP Lucey","year":"2018","unstructured":"Lucey BP, Hicks TJ, McLeland JS, et al. Effect of sleep on overnight cerebrospinal fluid amyloid \u03b2 kinetics. Ann Neurol. 2018;83(1):197\u2013204. https:\/\/doi.org\/10.1002\/ana.25117.","journal-title":"Ann Neurol"},{"issue":"6429","key":"2096_CR99","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1126\/science.aav2546","volume":"363","author":"JK Holth","year":"2019","unstructured":"Holth JK, Fritschi SK, Wang C, et al. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science. 2019;363(6429):880\u20134. https:\/\/doi.org\/10.1126\/science.aav2546.","journal-title":"Science"},{"key":"2096_CR100","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neurobiolaging.2020.02.020","volume":"91","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yan XD, Wang C, et al. Suvorexant ameliorates cognitive impairments and pathology in APP\/PS1 transgenic mice. Neurobiol Aging. 2020;91:66\u201375. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2020.02.020.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2096_CR101","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/ana.26641","volume":"94","author":"BP Lucey","year":"2023","unstructured":"Lucey BP, Liu H, Toedebusch CD, et al. Suvorexant acutely decreases tau phosphorylation and A\u03b2 in the human CNS. Ann Neurol. 2023;94(1):27\u201340. https:\/\/doi.org\/10.1002\/ana.26641.","journal-title":"Ann Neurol"},{"key":"2096_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109815","volume":"245","author":"M Carpi","year":"2024","unstructured":"Carpi M, Palagini L, Fernandes M, et al. Clinical usefulness of dual orexin receptor antagonism beyond insomnia: neurological and psychiatric comorbidities. Neuropharmacology. 2024;245: 109815. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109815.","journal-title":"Neuropharmacology"},{"issue":"15","key":"2096_CR103","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s40265-014-0294-5","volume":"74","author":"LPH Yang","year":"2014","unstructured":"Yang LPH. Suvorexant: first global approval. Drugs. 2014;74(15):1817\u201322. https:\/\/doi.org\/10.1007\/s40265-014-0294-5.","journal-title":"Drugs"},{"issue":"4","key":"2096_CR104","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40265-020-01276-1","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ. Lemborexant: first approval. Drugs. 2020;80(4):425\u201332. https:\/\/doi.org\/10.1007\/s40265-020-01276-1.","journal-title":"Drugs"},{"issue":"5","key":"2096_CR105","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","volume":"82","author":"A Markham","year":"2022","unstructured":"Markham A. Daridorexant: first approval. Drugs. 2022;82(5):601\u20137. https:\/\/doi.org\/10.1007\/s40265-022-01699-y.","journal-title":"Drugs"},{"issue":"3","key":"2096_CR106","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1124\/jpet.115.225466","volume":"354","author":"P Bonaventure","year":"2015","unstructured":"Bonaventure P, Shelton J, Yun S, et al. Characterization of JNJ-42847922, a selective orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia. J Pharmacol Exp Ther. 2015;354(3):471\u201382. https:\/\/doi.org\/10.1124\/jpet.115.225466.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"2096_CR107","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41386-021-01175-3","volume":"47","author":"VL Revell","year":"2022","unstructured":"Revell VL, Della Monica C, Mendis J, et al. Effects of the selective orexin-2 receptor antagonist JNJ-48816274 on sleep initiated in the circadian wake maintenance zone: a randomised trial. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2022;47(3):719\u201327. https:\/\/doi.org\/10.1038\/s41386-021-01175-3.","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol."},{"issue":"7","key":"2096_CR108","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jagp.2017.03.004","volume":"25","author":"WJ Herring","year":"2017","unstructured":"Herring WJ, Connor KM, Snyder E, et al. Suvorexant in elderly patients with insomnia: pooled analyses of data from phase iii randomized controlled clinical trials. Am J Geriatr Psychiatry. 2017;25(7):791\u2013802. https:\/\/doi.org\/10.1016\/j.jagp.2017.03.004.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"11","key":"2096_CR109","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.5664\/jcsm.6800","volume":"13","author":"P Murphy","year":"2017","unstructured":"Murphy P, Moline M, Mayleben D, et al. Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a bayesian, adaptive, randomized, double-blind, placebo-controlled study. J Clin Sleep Med. 2017;13(11):1289\u201399. https:\/\/doi.org\/10.5664\/jcsm.6800.","journal-title":"J Clin Sleep Med"},{"issue":"4","key":"2096_CR110","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s40120-024-00622-9","volume":"13","author":"V Arnold","year":"2024","unstructured":"Arnold V, Ancoli-Israel S, Dang-Vu TT, et al. Efficacy of lemborexant in adults \u2265 65 years of age with insomnia disorder. Neurol Ther. 2024;13(4):1081\u201398. https:\/\/doi.org\/10.1007\/s40120-024-00622-9.","journal-title":"Neurol Ther."},{"issue":"10","key":"2096_CR111","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s40266-022-00977-4","volume":"39","author":"I Fietze","year":"2022","unstructured":"Fietze I, Bassetti CLA, Mayleben DW, Pain S, Seboek Kinter D, McCall WV. Efficacy and safety of daridorexant in older and younger adults with insomnia disorder: a secondary analysis of a randomised placebo-controlled trial. Drugs Aging. 2022;39(10):795\u2013810. https:\/\/doi.org\/10.1007\/s40266-022-00977-4.","journal-title":"Drugs Aging"},{"issue":"2","key":"2096_CR112","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/0269881118822258","volume":"33","author":"S Brooks","year":"2019","unstructured":"Brooks S, Jacobs GE, De Boer P, et al. The selective orexin-2 receptor antagonist seltorexant improves sleep: an exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. J Psychopharmacol (Oxf). 2019;33(2):202\u20139. https:\/\/doi.org\/10.1177\/0269881118822258.","journal-title":"J Psychopharmacol (Oxf)."},{"issue":"1","key":"2096_CR113","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41398-019-0553-z","volume":"9","author":"K Recourt","year":"2019","unstructured":"Recourt K, De Boer P, Zuiker R, et al. The selective orexin-2 antagonist seltorexant (JNJ-42847922\/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. Transl Psychiatry. 2019;9(1):216. https:\/\/doi.org\/10.1038\/s41398-019-0553-z.","journal-title":"Transl Psychiatry"},{"issue":"1","key":"2096_CR114","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41398-020-00937-9","volume":"10","author":"G Salvadore","year":"2020","unstructured":"Salvadore G, Bonaventure P, Shekhar A, et al. Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans. Transl Psychiatry. 2020;10(1):308. https:\/\/doi.org\/10.1038\/s41398-020-00937-9.","journal-title":"Transl Psychiatry"},{"issue":"4","key":"2096_CR115","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s12264-019-00447-9","volume":"36","author":"Y Han","year":"2020","unstructured":"Han Y, Yuan K, Zheng Y, Lu L. Orexin receptor antagonists as emerging treatments for psychiatric disorders. Neurosci Bull. 2020;36(4):432\u201348. https:\/\/doi.org\/10.1007\/s12264-019-00447-9.","journal-title":"Neurosci Bull"},{"issue":"4","key":"2096_CR116","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1021\/acs.jmedchem.3c01894","volume":"67","author":"JT Williams","year":"2024","unstructured":"Williams JT, Bolli MH, Brotschi C, et al. Discovery of nivasorexant (ACT-539313): the first selective orexin-1 receptor antagonist (SO1RA) investigated in clinical trials. J Med Chem. 2024;67(4):2337\u201348. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01894.","journal-title":"J Med Chem"},{"issue":"3","key":"2096_CR117","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/alz.12035","volume":"16","author":"WJ Herring","year":"2020","unstructured":"Herring WJ, Ceesay P, Snyder E, et al. Polysomnographic assessment of suvorexant in patients with probable Alzheimer\u2019s disease dementia and insomnia: a randomized trial. Alzheimers Dement J Alzheimers Assoc. 2020;16(3):541\u201351. https:\/\/doi.org\/10.1002\/alz.12035.","journal-title":"Alzheimers Dement J Alzheimers Assoc."},{"issue":"1","key":"2096_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14283\/jpad.2020.69","volume":"8","author":"M Moline","year":"2020","unstructured":"Moline M, Thein S, Bsharat M, et al. Safety and efficacy of lemborexant in patients with irregular sleep-wake rhythm disorder and Alzheimer\u2019s disease dementia: results from a phase 2 randomized clinical trial. J Prev Alzheimers Dis. 2020;8(1):1\u201312. https:\/\/doi.org\/10.14283\/jpad.2020.69.","journal-title":"J Prev Alzheimers Dis."},{"issue":"2","key":"2096_CR119","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/0004867417747402","volume":"52","author":"A Hamuro","year":"2018","unstructured":"Hamuro A, Honda M, Wakaura Y. Suvorexant for the treatment of insomnia in patients with Alzheimer\u2019s disease. Aust N Z J Psychiatry. 2018;52(2):207\u20138. https:\/\/doi.org\/10.1177\/0004867417747402.","journal-title":"Aust N Z J Psychiatry"},{"issue":"4","key":"2096_CR120","doi-asserted-by":"publisher","first-page":"547","DOI":"10.9758\/cpn.2019.17.4.547","volume":"17","author":"T Hanazawa","year":"2019","unstructured":"Hanazawa T, Kamijo Y. Effect of suvorexant on nocturnal delirium in elderly patients with Alzheimer\u2019s disease: a case-series study. Clin Psychopharmacol Neurosci. 2019;17(4):547\u201350. https:\/\/doi.org\/10.9758\/cpn.2019.17.4.547.","journal-title":"Clin Psychopharmacol Neurosci."},{"issue":"30","key":"2096_CR121","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021043","volume":"99","author":"S Xu","year":"2020","unstructured":"Xu S, Cui Y, Shen J, Wang P. Suvorexant for the prevention of delirium: a meta-analysis. Medicine (Baltimore). 2020;99(30): e21043. https:\/\/doi.org\/10.1097\/MD.0000000000021043.","journal-title":"Medicine (Baltimore)"},{"key":"2096_CR122","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.genhosppsych.2023.06.019","volume":"84","author":"T Nakamura","year":"2023","unstructured":"Nakamura T, Yoshizawa T, Toya R, et al. Orexin receptor antagonists versus antipsychotics for the management of delirium in intensive care unit patients with cardiovascular disease: a retrospective observational study. Gen Hosp Psychiatry. 2023;84:96\u2013101. https:\/\/doi.org\/10.1016\/j.genhosppsych.2023.06.019.","journal-title":"Gen Hosp Psychiatry"},{"issue":"9","key":"2096_CR123","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1093\/brain\/aws190","volume":"135","author":"DHJ Davis","year":"2012","unstructured":"Davis DHJ, Muniz Terrera G, Keage H, et al. Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study. Brain. 2012;135(9):2809\u201316. https:\/\/doi.org\/10.1093\/brain\/aws190.","journal-title":"Brain"},{"issue":"6","key":"2096_CR124","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/gps.5088","volume":"34","author":"TG Fong","year":"2019","unstructured":"Fong TG, Vasunilashorn SM, Libermann T, Marcantonio ER, Inouye SK. Delirium and Alzheimer\u2019s disease: a proposed model for shared pathophysiology. Int J Geriatr Psychiatry. 2019;34(6):781\u20139. https:\/\/doi.org\/10.1002\/gps.5088.","journal-title":"Int J Geriatr Psychiatry"},{"key":"2096_CR125","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00974-6","author":"H Fagan","year":"2022","unstructured":"Fagan H, Jones E, Baldwin DS. Orexin receptor antagonists in the treatment of depression: a leading article summarising pre-clinical and clinical studies. CNS Drugs. 2022. https:\/\/doi.org\/10.1007\/s40263-022-00974-6.","journal-title":"CNS Drugs"},{"issue":"1","key":"2096_CR126","doi-asserted-by":"publisher","first-page":"77","DOI":"10.29399\/npa.28383","volume":"61","author":"M U\u011furlu","year":"2024","unstructured":"U\u011furlu M. Orexin receptor antagonists as adjunct drugs for the treatment of depression: a mini meta-analysis. Noro Psikiyatri Arsivi. 2024;61(1):77\u201384. https:\/\/doi.org\/10.29399\/npa.28383.","journal-title":"Noro Psikiyatri Arsivi."},{"issue":"6","key":"2096_CR127","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1177\/0269881118773745","volume":"32","author":"P De Boer","year":"2018","unstructured":"De Boer P, Drevets WC, Rofael H, et al. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. J Psychopharmacol (Oxf). 2018;32(6):668\u201377. https:\/\/doi.org\/10.1177\/0269881118773745.","journal-title":"J Psychopharmacol (Oxf)."},{"issue":"12","key":"2096_CR128","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/ijnp\/pyab050","volume":"24","author":"A Savitz","year":"2021","unstructured":"Savitz A, Wajs E, Zhang Y, et al. Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: a phase 2b, randomized, placebo-controlled adaptive dose-finding study. Int J Neuropsychopharmacol. 2021;24(12):965\u201376. https:\/\/doi.org\/10.1093\/ijnp\/pyab050.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"2096_CR129","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/JGP.0b013e31816029ec","volume":"16","author":"MA Rapp","year":"2008","unstructured":"Rapp MA, Schnaider-Beeri M, Purohit DP, Perl DP, Haroutunian V, Sano M. Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression. Am J Geriatr Psychiatry. 2008;16(2):168\u201374. https:\/\/doi.org\/10.1097\/JGP.0b013e31816029ec.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"2096_CR130","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejphar.2009.10.022","volume":"626","author":"F Caraci","year":"2010","unstructured":"Caraci F, Copani A, Nicoletti F, Drago F. Depression and Alzheimer\u2019s disease: neurobiological links and common pharmacological targets. Eur J Pharmacol. 2010;626(1):64\u201371. https:\/\/doi.org\/10.1016\/j.ejphar.2009.10.022.","journal-title":"Eur J Pharmacol"},{"key":"2096_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.631770","volume":"13","author":"JA Santiago","year":"2021","unstructured":"Santiago JA, Potashkin JA. The impact of disease comorbidities in Alzheimer\u2019s disease. Front Aging Neurosci. 2021;13: 631770. https:\/\/doi.org\/10.3389\/fnagi.2021.631770.","journal-title":"Front Aging Neurosci."},{"issue":"2","key":"2096_CR132","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/JGP.0b013e318187de18","volume":"17","author":"PR Gehrman","year":"2009","unstructured":"Gehrman PR, Connor DJ, Martin JL, Shochat T, Corey-Bloom J, Ancoli-Israel S. Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2009;17(2):166\u20139. https:\/\/doi.org\/10.1097\/JGP.0b013e318187de18.","journal-title":"Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry."},{"issue":"2","key":"2096_CR133","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/psyg.12191","volume":"17","author":"FM Scoralick","year":"2017","unstructured":"Scoralick FM, Louzada LL, Quintas JL, Naves JOS, Camargos EF, N\u00f3brega OT. Mirtazapine does not improve sleep disorders in Alzheimer\u2019s disease: results from a double-blind, placebo-controlled pilot study. Psychogeriatr Off J Jpn Psychogeriatr Soc. 2017;17(2):89\u201396. https:\/\/doi.org\/10.1111\/psyg.12191.","journal-title":"Psychogeriatr Off J Jpn Psychogeriatr Soc."},{"issue":"3","key":"2096_CR134","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/jnnp.2006.104034","volume":"78","author":"J Ellul","year":"2006","unstructured":"Ellul J, Archer N, Foy CML, et al. The effects of commonly prescribed drugs in patients with Alzheimer\u2019s disease on the rate of deterioration. J Neurol Neurosurg Psychiatry. 2006;78(3):233\u20139. https:\/\/doi.org\/10.1136\/jnnp.2006.104034.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2096_CR135","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.1136\/bmj.g5205","volume":"349","author":"S Billioti De Gage","year":"2014","unstructured":"Billioti De Gage S, Moride Y, Ducruet T, et al. Benzodiazepine use and risk of Alzheimer\u2019s disease: case-control study. BMJ. 2014;349:5205. https:\/\/doi.org\/10.1136\/bmj.g5205.","journal-title":"BMJ"},{"issue":"4","key":"2096_CR136","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13229","volume":"30","author":"J Blackman","year":"2021","unstructured":"Blackman J, Swirski M, Clynes J, Harding S, Leng Y, Coulthard E. Pharmacological and non-pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer\u2019s disease: a systematic review. J Sleep Res. 2021;30(4): e13229. https:\/\/doi.org\/10.1111\/jsr.13229.","journal-title":"J Sleep Res"},{"key":"2096_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2020.101375","volume":"55","author":"C Liguori","year":"2021","unstructured":"Liguori C, Maestri M, Spanetta M, et al. Sleep-disordered breathing and the risk of Alzheimer\u2019s disease. Sleep Med Rev. 2021;55: 101375. https:\/\/doi.org\/10.1016\/j.smrv.2020.101375.","journal-title":"Sleep Med Rev"},{"key":"2096_CR138","doi-asserted-by":"publisher","DOI":"10.3791\/58823","author":"CD Toedebusch","year":"2019","unstructured":"Toedebusch CD, McLeland JS, Schaibley CM, et al. Multi-modal home sleep monitoring in older adults. J Vis Exp JoVE. 2019. https:\/\/doi.org\/10.3791\/58823.","journal-title":"J Vis Exp JoVE."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02096-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02096-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02096-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T03:41:41Z","timestamp":1732765301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02096-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":138,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2096"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02096-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"9 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Roma Tor Vergata within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Claudio Liguori has received honoraria from Idorsia, EISAI, and MSD for research support or advisory board participation. Claudio Liguori has participated as investigator in the clinical trials by Takeda. Matteo Carpi and Nicola Biagio Mercuri have no relevant financial or non-financial interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"An ethics statement is not applicable as this study is based exclusively on published literature and publicly available information on registered clinical trials.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data supporting the findings of this study are available within the article. The corresponding author can be contacted for further inquiries.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the conception and design of the study. Matteo Carpi and Claudio Liguori performed the literature search and review. Nicola Biagio Mercuri provided critical supervision. The first draft of the manuscript was written by Matteo Carpi and Claudio Liguori, and all authors commented on earlier versions of the manuscript. All authors read and approved the final version of the manuscript and agreed to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}